Phase II trials in the era of glioblastoma immunotherapy: New mechanisms of action, familiar challenges in trial design and tumor response assessment

Neuro Oncol. 2023 Jun 2;25(6):1098-1099. doi: 10.1093/neuonc/noad043.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Glioblastoma* / drug therapy
  • Glioblastoma* / pathology
  • Humans
  • Immunoconjugates*
  • Immunotherapy / methods
  • Receptors, Interleukin-4

Substances

  • Receptors, Interleukin-4
  • Immunoconjugates